Skip to content
Company Analysis

Cue Biopharma, Inc. CUE

A comprehensive view of key metrics, scores, and financial health for Cue Biopharma, Inc.

Overview of Cue Biopharma, Inc.

CUE NCM
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Micro Cap
Cue Biopharma, Inc. (CUE), is a Micro Cap company, in the Biotechnology industry, last closed at $21.16, about 91.8% overvalued vs fair value, +2.2% 1Y return, ranked 882/1145 in sector.
Metrics Rev Growth 195.8% ROE -121.1%
USD 21.16
15.50%
(Delayed)
• Vol 90d: 133.7%
52-Week Range
Market Cap
$153.72M
Enterprise Value
$136.32M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 82%
Confidence: 89%
Updated: Oct 24
Top Beats

Quick Facts

Website https://www.cuebiopharma.com
HQ Boston, MA
Employees 41
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$1
$2
$2
Current: $21.16 -92% vs base

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$27.1M
20.8%%
Total Revenue
$27.5M
195.7%%
Net Income
-$26.6M
34.6%%
Operating Expense
$54.0M
6.1%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
15.0 months
Fair

Limited runway, likely needs financing within a year

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Cue Biopharma, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
54
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Scale Supporting Profitability Profitability at scale is strong (score 0.86), demonstrating competitive advantages.
  • Cash Generation Consistent Cash generation is consistent (score 0.73), indicating reliable business model.

Key risks

  • ROIC Below WACC or Peers ROIC at 37.2th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.38), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
42
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 67% Coverage
Trade-Off Triangle Visualization A ternary plot showing CUE's balance between Growth (15.8%), Profitability (34.9%), and Safety (49.3%). Growth 16% Safety 49% Profitability 35%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

15th percentile vs peers
15
Key Signals
TSR -74.8% 15p
Strengths

No notable strengths identified for this axis.

Risks
  • Growth in bottom 20% of peers (percentile: 15)

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

47th percentile vs peers
47
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Cue Biopharma, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$1.73
- - -
-91.8% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000